News

Video

Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial

Author(s):

SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.

Video Player is loading.
Current Time 0:00
Duration 26:05
Loaded: 0%
Stream Type LIVE
Remaining Time 26:05
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected